Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research crawled date : 2022 - 12 - 15 save search
Ocean Power Technologies to Participate in a Fireside Chat with Water Tower Research on Friday, December 16
Published: 2022-12-15 (Crawled : 23:00) - globenewswire.com
OPTT | $0.195 -7.14% 0.0% 760K
|
Producer Manufacturing
|
| O: -3.0%
H: 3.09%
C: 3.09%
water research
TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments
Published: 2022-12-15 (Crawled : 21:00) - biospace.com/
MTAC 4 | $11.34 18.67% 180K
|
|
| O: 2.73%
H: 0.0%
C: -3.09%
sciences research pre-clinical life trial
Negative Pressure Wound Therapy Market Size to Reach USD 4.27 Billion in 2030| Emergen Research
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
STMH | $0.1 -88.3% 2.2K
|
Manufacturing
|
| O: 0.0%
H: 21.21%
C: 21.21%
CAH | $106.0 -0.49% -0.94% 1.5M
|
Distribution Services
|
| O: -0.64%
H: 0.97%
C: 0.67%
MMM | $91.48 0.57% 0.0% 3M
|
Producer Manufacturing
|
| O: -1.03%
H: 0.23%
C: -1.93%
SMTI | News A | $34.2 8.23% 7.6% 24K
|
Health Services
|
| O: -1.61%
H: 6.87%
C: 4.34%
research therapy negative market
Global Rare Disease Drugs Market Report 2022-2027: Increasing Focus on Research Activities and Development of Novel Therapeutic Drugs to Facilitate Future Growth
Published: 2022-12-15 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.71%
H: 0.07%
C: -1.05%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.71%
H: 0.08%
C: -1.07%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.59%
H: 0.44%
C: -0.48%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
rare research global disease report growth market
Interactive Display Market Size to Reach USD 18.81 Billion in 2030| Emergen Research
Published: 2022-12-15 (Crawled : 17:00) - prnewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
research market
Chili's celebrates $100 million raised to benefit St. Jude Children's Research Hospital
Published: 2022-12-15 (Crawled : 15:20) - prnewswire.com
EAT | $45.3 2.79% 0.0% 2.8M
|
Consumer Services
|
| O: -1.85%
H: 1.17%
C: 0.11%
research
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
EHVVF | $0.001 155.0% 34K
|
Professional, Scientific, and T...
|
| O: 13.56%
H: 11.94%
C: 4.48%
fda ketamine grants study major depressive disorder
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
RLYB | $1.68 -4.55% -4.76% 350K
|
|
| O: 9.83%
H: 10.53%
C: 1.3%
publication
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
Published: 2022-12-15 (Crawled : 14:20) - biospace.com/
SEEL | $0.322 -3.01% -3.11% 270K
|
Health Technology
|
| O: 3.1%
H: 0.0%
C: -18.05%
sls-004 disease parkinson's therapeutics therapy study
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -2.18%
H: 0.0%
C: -0.83%
fx-345 candidate therapeutics study phase 2b
Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental SystemsNew Collaboration to Increase Payer Reimbursements and Patient Access
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
VVOS | $2.66 -2.66% 63K
|
Health Technology
|
| O: 0.0%
H: 4.88%
C: 0.72%
collaboration medical therapeutics
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular EdemaRZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
RZLT 4 | $3.305 2.01% 1.97% 280K
|
Technology Services
|
| O: 0.66%
H: 2.61%
C: -2.61%
rz402 macular eye alternative potential therapy study diabetic
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
BCRX | $4.49 -1.97% -2.0% 3M
|
Health Technology
|
| O: -6.0%
H: 8.76%
C: 2.95%
bcx9930 potential
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
TLSA | News | $0.6199 20.84% 17.24% 1.5M
|
Health Technology
|
| O: 1.95%
H: 0.7%
C: 0.7%
sciences pre-clinical life study
Immunocore is awarded the Prix Galien France award for KIMMTRAK
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
IMCR | $54.765 0.34% 0.34% 430K
|
Manufacturing
|
| O: -1.17%
H: 4.5%
C: 1.97%
award kimmtrak
Zentek Announces Successful Phase 2 Results of HVAC Testing
Published: 2022-12-15 (Crawled : 13:20) - biospace.com/
ZTEK | $1.14 1.33% 13K
|
Professional, Scientific, and T...
|
| O: 2.89%
H: 0.0%
C: -6.74%
IKTSY | $60.25 -12.21% 4.2K
|
Professional, Scientific, and T...
|
| O: -1.86%
H: 0.0%
C: -0.96%
results phase 2
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: -1.17%
H: 0.48%
C: -0.55%
lynparza treatment review update cancer prostate cancer
Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
ATXS | $10.56 0.1% 0.09% 320K
|
Manufacturing
|
| O: 8.99%
H: 10.83%
C: -6.17%
star-0215 trial therapeutics positive results
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
RVPH | $3.03 -5.31% -5.61% 120K
|
|
| O: 2.48%
H: 11.35%
C: -0.72%
pharmaceuticals brilaroxazine positive study
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
|
| O: 30.33%
H: 0.0%
C: 0.0%
ongoing trial phase 2b
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.